Fresenius Kabi USA, LLC

Form 483 issued May 14, 2026 · Grand Island, New York

Inspection
May 5 – May 14, 2026
Observations
2
Pages
4
FEI number
3001833549

In short: On May 14, 2026, FDA issued a Form 483 with 2 observations to Fresenius Kabi USA, LLC in Grand Island, New York (FEI 3001833549) after an inspection that ran May 5 – May 14, 2026. The investigators were Joshrenzo N. Ramilo and Mindy M. Chou. Most observations concern production; the most-cited regulation is 21 CFR 211.100 (written procedures; deviations).

At a glance

2 of 2 observations on this 483 concern production.

Production2

Most cited: 21 CFR 211.100 (1×) · 211.113 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Your firm failed to establish adequate written procedures for production and process controls designed to assure…

  2. 02

    Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Fresenius Kabi USA, LLC?

FDA listed 2 observations on this Form 483, mostly about production. The most-cited regulation is 21 CFR 211.100 (written procedures; deviations). The opening words of each observation are shown on this page.

Who inspected Fresenius Kabi USA, LLC?

Joshrenzo N. Ramilo and Mindy M. Chou are named on this Form 483, for the inspection of May 5 – May 14, 2026. Each investigator has a profile showing what they cite most.

When was Fresenius Kabi USA, LLC inspected by FDA?

The inspection ran May 5 – May 14, 2026, and the Form 483 is dated May 14, 2026.

How do I get the full Form 483 for Fresenius Kabi USA, LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free